Glenmede Trust Co. NA lowered its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 2.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 715,954 shares of the company’s stock after selling 14,814 shares during the period. Glenmede Trust Co. NA owned approximately 0.07% of Eli Lilly and worth $60,467,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Gradient Investments LLC acquired a new stake in Eli Lilly and during the fourth quarter worth approximately $103,000. Avestar Capital LLC acquired a new stake in Eli Lilly and during the fourth quarter worth approximately $100,000. MPS Loria Financial Planners LLC acquired a new stake in Eli Lilly and during the second quarter worth approximately $128,000. San Francisco Sentry Investment Group CA acquired a new stake in Eli Lilly and during the second quarter worth approximately $129,000. Finally, Willingdon Wealth Management acquired a new stake in Eli Lilly and during the third quarter worth approximately $138,000. 77.58% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have commented on LLY shares. Jefferies Group set a $93.00 price objective on Eli Lilly and and gave the company a “buy” rating in a research note on Monday, February 26th. JPMorgan Chase & Co. set a $105.00 price objective on Eli Lilly and and gave the company a “buy” rating in a research note on Monday, February 26th. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and raised their price objective for the company from $85.52 to $115.00 in a research note on Friday, January 5th. TheStreet cut Eli Lilly and from a “b” rating to a “c” rating in a research note on Monday, March 5th. Finally, Morgan Stanley raised their price objective on Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 21st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $93.47.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. Eli Lilly and’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.95 earnings per share. research analysts forecast that Eli Lilly and Co will post 4.87 EPS for the current year.
In related news, insider Donald A. Zakrowski sold 860 shares of Eli Lilly and stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $76.50, for a total transaction of $65,790.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Donald A. Zakrowski sold 900 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the transaction, the insider now directly owns 4,130 shares in the company, valued at approximately $334,901.70. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,261 shares of company stock worth $987,485. 0.20% of the stock is owned by insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.